Patent · US Active

Methods for assessing responsiveness of B-cell lymphoma to treatment with anti-CD40 antibodies

US9617600B2 · kind B2 · utility

0Cited by
27References
16Claims
0Family size

Assignee

Inventors

Key dates

Filing dateApr 17, 2010
Grant dateApr 11, 2017
Priority date
Expiry dateOct 7, 2030

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12Q2600/158
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The invention provides methods and kits useful for predicting or assessing responsiveness of a patient having B-cell lymphoma to treatment with anti-CD40 antibodies.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.